证券代码：000952 证券简称：广济药业 公告编号：2025-039 湖北广济药业股份有限公司 关于公司聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会秘书离任情况 湖北广济药业股份有限公司（以下简称"公司"）董事会秘书郑彬先生因工 作岗位调动原因，不再担任公司董事会秘书职务，但仍在公司任职。其岗位调动 不会影响董事会的正常运作及公司日常经营管理。 郑彬先生在担任公司董事会秘书期间，在公司治理、资本运作、信息披露、 投资者关系管理等方面勤勉敬业，恪尽职守。公司董事会对郑彬先生在其任职期 间所做的贡献表示衷心感谢！ 二、聘任董事会秘书情况 公司于 2025 年 7 月 21 日召开第十一届董事会第九次（临时）会议，审议通 过《关于聘任杨行虎先生为公司董事会秘书的议案》，经公司董事会提名委员会 资格审查通过，建议聘任杨行虎先生为公司董事会秘书（个人简历附后），任期 自本次董事会通过之日起至第十一届董事会届满日止。 杨行虎先生具备履行董事会秘书职责所必需的财务、管理、法律专业知识， 具有良好的职业道德和个人品德，并于 2025 年 ...

湖北广济药业股份有限公司 关于公司副总经理辞职的公告 证券代码：000952 证券简称：广济药业 公告编号：2025-040 特此公告。 湖北广济药业股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2025 年 7 月 21 日 湖北广济药业股份有限公司（以下简称"公司"）董事会于近日收到副总经 理胡明峰先生递交的书面辞职报告，因工作岗位调动原因，胡明峰先生申请辞去 公司副总经理职务。辞任后，胡明峰先生仍在公司任职。 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号－－主板上市公司规范运作》和《公司章 程》的有关规定，胡明峰先生的辞职报告自送达公司董事会之日起生效，其辞职 不会对公司的正常运营产生影响。 胡明峰先生原定任期至公司第十一届董事会届满之日止。截至本公告披露之 日，胡明峰先生持有公司 2021 年限制性股票激励计划已获授但尚未解除限售的 限制性股票 66,000 股，其股份变动将严格遵循《公司 2021 年限制性股票激励计 划》《公司 2021 年限制性股票激励计划实施考核 ...

2、会议的时间和方式：2025 年 7 月 21 日上午 10 点在湖北广济药业股份有 限公司（以下简称"公司"）武穴市大金产业园行政楼二楼会议室以现场结合通 讯的方式召开； 3、本次会议应到董事 9 人（含独立董事 3 人），实到董事 9 人，龚铖先生、 郭韶智先生为现场表决，胡立刚先生、方智先生、刘波先生、石守东先生、郭炜 先生、洪葵女士、梅建明先生为通讯表决； 证券代码：000952 证券简称：广济药业 公告编号：2025-038 湖北广济药业股份有限公司 第十一届董事会第九次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1、会议通知的时间和方式：会议通知于 2025 年 7 月 14 日以专人送达、书 面传真和电子邮件形式发出； 4、本次会议由董事长胡立刚先生主持，全体监事列席本次会议； 5、本次会议的召开符合《中华人民共和国公司法》和《公司章程》的有关 规定，会议决议合法、有效。 二、董事会会议审议情况 审议通过《关于聘任杨行虎先生为公司董事会秘书的议案》 经董事会提名委员会资格审查，同意聘任杨行虎先生 ...

Summary of Key Points Core Viewpoint - The company, Hubei Guangji Pharmaceutical Co., Ltd., has announced an expected net profit loss for the first half of 2025, indicating challenges in financial performance despite some operational improvements [1]. Financial Performance - The performance forecast period is from January 1, 2025, to June 30, 2025, with an anticipated net profit being negative [1]. - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies noted [1]. Reasons for Performance Changes - The increase in net profit attributable to shareholders compared to the same period last year is primarily due to: 1. Implementation of a "streamlined and efficient" management approach, reducing management levels and internal departments, which has improved management efficiency and lowered costs [1]. 2. The Jining company has reduced production in response to market conditions, leading to a decrease in unnecessary personnel and a reduction in losses compared to the previous year [1]. 3. Strengthened market cooperation and enhanced customer communication have resulted in increased sales for certain product specifications in both raw materials and formulations compared to the previous year [1].

[Hubei Guangji Pharmaceutical Co., Ltd. 2025 Interim Results Forecast](index=1&type=section&id=%E6%B9%96%E5%8C%97%E5%B9%BF%E6%B5%8E%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) The company forecasts a continued net loss for H1 2025, but with a significant year-over-year reduction [Performance Forecast for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a net loss attributable to shareholders for H1 2025, but with a notable reduction compared to the prior year H1 2025 Performance Forecast | Item | Current Reporting Period | Same Period Last Year | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | **Loss: RMB 67.00 million - 83.50 million** | Loss: RMB 106.65 million | | YoY Change | Loss Reduction: 21.70% - 37.17% | - | | **Net Profit after Non-recurring Items** | **Loss: RMB 70.00 million - 86.50 million** | Loss: RMB 115.67 million | | YoY Change | Loss Reduction: 25.22% - 39.48% | - | | **Basic Earnings Per Share** | **Loss: RMB 0.1915/share - 0.2387/share** | Loss: RMB 0.3014/share | [Communication with the Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company has communicated with its accounting firm regarding the forecast, with no disagreements on the content - The company has pre-communicated with its accounting firm regarding the performance forecast, and **no disagreements exist** between the two parties[4](index=4&type=chunk) - This performance forecast **has not been audited** by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The year-over-year improvement in net profit is attributed to cost reduction, subsidiary adjustments, and sales growth [Management Optimization and Cost Control](index=1&type=section&id=3.1%20%E7%AE%A1%E7%90%86%E4%BC%98%E5%8C%96%E4%B8%8E%E6%88%90%E6%9C%AC%E6%8E%A7%E5%88%B6) The company enhanced management efficiency and lowered costs by streamlining its organizational structure - During the reporting period, the company restructured its management organization based on the principle of **'streamlined and efficient'** to improve management effectiveness and reduce administrative costs[5](index=5&type=chunk) [Subsidiary Operational Adjustments](index=1&type=section&id=3.2%20%E5%AD%90%E5%85%AC%E5%8F%B8%E7%BB%8F%E8%90%A5%E8%B0%83%E6%95%B4) The Jining subsidiary reduced its losses year-over-year by scaling back production and personnel due to unfavorable market prices - The Jining subsidiary **reduced its losses year-over-year** by systematically scaling back production and non-essential personnel in response to lower-than-expected market prices[5](index=5&type=chunk) [Market and Sales Expansion](index=1&type=section&id=3.3%20%E5%B8%82%E5%9C%BA%E4%B8%8E%E9%94%80%E5%94%AE%E6%8B%93%E5%B1%95) The company achieved sales growth for certain products by strengthening market cooperation and expanding sales channels - The company achieved **year-over-year sales growth** for certain specifications of its raw material and formulation series products by strengthening market partnerships and expanding sales channels[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The performance forecast is a preliminary estimate, and final data will be in the official interim report - This performance forecast is a preliminary result from the company's finance department; specific financial data will be based on the **official 2025 interim report**[6](index=6&type=chunk) - Investors are advised to **make prudent decisions** and be aware of investment risks[6](index=6&type=chunk)

Core Viewpoint - Guangji Pharmaceutical (000952) has received approval from the National Health Commission for its application of 2'-fucosyllactose, a significant step towards the product's industrialization [1] Group 1: Product Approval - The application for 2'-fucosyllactose has passed the administrative review and has been officially announced [1] - 2'-fucosyllactose is a oligosaccharide abundant in breast milk, known for its benefits in regulating gut microbiota, promoting brain development, and enhancing immunity [1] - The product is included in the list of food nutrition fortifiers, allowing its use in infant formula and milk powder [1] Group 2: Research and Development - The successful approval of 2'-fucosyllactose is a result of the company's independent research and development efforts [1] - The approval meets national technical review standards, laying a solid foundation for the company's advancement in product industrialization [1]

证券代码：000952 证券简称：广济药业 公告编号：2025-036 湖北广济药业股份有限公司 关于 2'-岩藻糖基乳糖获批的自愿性披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，湖北广济药业股份有限公司（以下简称"公司"）收到中华人民共和 国国家卫生健康委员会《行政许可审查结论通知书》（卫食添通字[2025]第 0023 号），公司提交的关于 2'-岩藻糖基乳糖(卫食添新申字(2025)第 0010 号)的行政 许可申请，根据《食品安全法》和《食品添加剂新品种管理办法》，经国家卫生 健康委员会审查通过并已公告。现将相关情况公告如下： 一、批文基本信息 1、中文名称：2'-岩藻糖基乳糖 2、英文名称：2'-fucosyllactose，2'-FL 3、功能分类：食品营养强化剂 4、生产菌信息：枯草芽孢杆菌 168 / Bacillus subtilis 168 二、2'-岩藻糖基乳糖相关信息 2'-岩藻糖基乳糖是母乳中含量丰富的低聚糖，具有调节肠道菌群、促进大脑 发育和提升免疫力等功能。根据中华人民共和国国家卫生健康委员会 2023 年第 8 ...

Transaction Overview - Hubei Guangji Pharmaceutical Co., Ltd. announced the public transfer of 90% equity in its subsidiary Hubei Guangji Pharmaceutical Technology Co., Ltd. through the Shanghai United Assets and Equity Exchange [1][2] - The transfer price is set at RMB 44.7856 million, based on the assessed value of the equity [2][3] Transaction Progress - As of the announcement date, the company has received the property transaction certificate from the Shanghai United Assets and Equity Exchange, and the buyer has paid the full transaction price [4] - The subsidiary has completed the business registration change and obtained a new business license, now named Hubei Changjiang Ruiyi Pharmaceutical Technology Co., Ltd. [4] Post-Transaction Status - Following the completion of the business registration change, the company no longer holds shares in Hubei Changjiang Ruiyi Pharmaceutical Technology Co., Ltd. and will not consolidate it into its financial statements [5]

证券代码：000952 证券简称：广济药业 公告编号：2025-035 湖北广济药业股份有限公司 关于公开挂牌转让湖北广济医药科技有限公司 90%股权进展暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，湖北广济药业股份有限公司（以下简称"公司"）通过上海联合产权 交易所挂牌的方式公开转让所持有的控股子公司湖北广济医药科技有限公司（以 下简称"医药科技公司"）90%股权项目，完成了股权过户和工商变更登记手续， 现将相关情况公告如下： 一、交易概述 2024 年 9 月 20 日，公司拟在上海联合产权交易所预挂牌转让所持控股子公 司医药科技公司 90%股权。具体内容详见公司于 2024 年 9 月 21 日在巨潮资讯网 （http://www.cninfo.com.cn）、《中国证券报》《证券时报》《证券日报》《上 海证券报》披露的《关于预挂牌转让控股子公司湖北广济医药科技有限公司 90% 股权的提示性公告》（公告编号：2024-059）。 2024 年 10 月 29 日，公司召开第十一届董事会第二次会议、第十一届监事 会第二次会 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. faces a fine of 3.1 million yuan due to revenue recognition violations, with ongoing losses in recent years amid industry competition [1][2]. Group 1: Regulatory Issues - The violation dates back to October 25, 2024, when the company received a notice from the China Securities Regulatory Commission (CSRC) regarding suspected illegal information disclosure [2]. - Guangji Pharmaceutical's subsidiary, Hubei Guangji Jikang Pharmaceutical Co., Ltd., improperly recognized revenue using the gross method instead of the net method, leading to inflated revenue figures for the first three quarters of 2022 [2]. - The Hubei Securities Regulatory Bureau plans to impose a fine of 1.5 million yuan on the company, with additional fines of 800,000 yuan each for the chairman and the CFO [2]. Group 2: Financial Performance - Guangji Pharmaceutical has reported continuous losses, with a net loss of 140 million yuan in 2023, which expanded to 295 million yuan in 2024, and a further loss of 36.26 million yuan in the first quarter of 2025 [5][6]. - The company attributes its losses to increased R&D investments, intensified industry competition, and low market prices for its main products, particularly feed-grade vitamins B2 and B12 [5][6]. - The company has acknowledged that its production capacity from recent acquisitions has not been fully utilized, contributing to high costs and operational expenses [5]. Group 3: Company Response and Future Strategies - Following the revenue recognition issue, the company plans to enhance its internal controls and financial management practices to prevent future violations [6]. - Guangji Pharmaceutical is focusing on improving the competitiveness of its main products and optimizing its existing assets to mitigate losses [6]. - The company is also undergoing management reforms to address the challenges posed by low market prices and shrinking demand [6].